Picture [iito] Made Without Love 650x80px
Financing › Details

Lysogene–Sarepta: investment, 202003 capital increase totalling €7.7m incl €538k from existing + co-investor Sarepta Therapeutics


Period Period 2020-03-12
Organisations Money taker Lysogene S.A. (Euronext Paris: LYS)
  Money source Sarepta Therapeutics Inc. (NASDAQ: SRPT)
Products Product gene therapy
  Product 2 venture capital
Index term Index term Lysogene–SEVERAL: investment, 202003 capital increase €7.7m led by OrbiMed Advisors + incl Sarepta Therapeutics at €2.83/share
Document Source Lysogene S.A.. (3/12/20). "Press Release: Lysogene Completes €7.7 Million Capital Increase in a Placement Led by Leading Healthcare Investor OrbiMed and Lysogene Shareholder and Partner Sarepta [Not for US, CA, AU or JP]". Paris.

Record changed: 2020-12-15


Picture [iito] Made Without Love 650x80px

More documents for Lysogene S.A. (Euronext Paris: LYS)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top